Implications of the FDA/SEC Memorandum of Understanding
The 8/31 Memorandum of Understanding signed by FDA and the Securities and Exchange Commission (SEC) is a signal that statements to investors about FDA matters, such as regulatory submissions, clinical trial results, approval timelines, and inspection outcomes now face a more direct check against what FDA itself knows. That’s the analysis of attorneys Harper Beck and Thomas Krysa (Foley & Lardner), writing in an online post.
The attorneys say that while the SEC has long brought enforcement actions over misleading statements about FDA interactions, it often has had to rebuild the regulatory record through subpoenas and company productions. “Under the MOU,” they write, “each agency intends to share appropriate information about FDA-regulated products and activities, and about the persons and firms that make, distribute, and sell those products, ‘where practicable.’”
The post lists these key features of the framework:
- both enforcement and review are involved;
- FDA non-public information can be used broadly;
- information flows both ways;
- some statutory protections remain; and
- confidentiality and privilege are protected.
“Even without binding obligations, the MOU signals that FDA-related disclosures will be a priority for both SEC disclosure review and enforcement,” Beck and Krysa conclude. They say public companies in the pharmaceutical, biotechnology, medical device, and other FDA-regulated sectors should consider the following steps:
- reconcile public statements with the regulatory record;
- involve regulatory affairs in disclosure controls;
- expect more informed consent letters; and
- review insider trading controls around FDA events.